

Provider Update

January 4, 2022

DOH Deputy Secretary Laura C. Parajón, M.D., M.P.H
Infectious Disease Bureau Chief Dan Burke
NW Regional Health Officer Miranda Durham, M.D.

NM DOH Mission

To ensure health equity, we work with our partners to promote health and well-being, and improve health outcomes for all people in New Mexico.

Goals



We expand equitable access to services for all New Mexicans



We ensure safety in New Mexico healthcare environments



We improve health status for all New Mexicans



We support each other by promoting an environment of mutual respect, trust, open communication, and needed resources for staff to serve New Mexicans and to grow and reach their professional goals


Timeline:

- Phases open through 1C2. Friday 3.19.21
- Self scheduling for 75+ started 3.29.21
- Self scheduling for booster doses started Thursday 4.1.21
- All phases opened Monday 4.5.21
- Self scheduling for those 60+ started Thursday 4.8.21
- Janssen pause 4.12.21
- DOH posts event code online - on purpose! For MEGA event 4.16.21
- Self scheduling for 40+ starts Monday 4.19.21
- Janssen pause lifted 4.23.21
- Homebound button implemented 4.23.21
- Self Scheduling for 16+ starts Monday 4.26.21
- Age categories change on the dashboard 4.30.21 (now tracking 65+)
- Vaccine Event Request Form implemented 5.10.21
- Pfizer EUA expanded to include children aged 12 – 15. approved by ACIP Wednesday 5.12.21
- Pfizer EUA extends vaccine storage from 5 days to 31 days in the refrigerator 5.20.21
- NM announces state-wide vaccine lottery Tuesday 6.1.21
- 100\$ Incentive program for completed vaccine series Monday 6.14 – Thursday 6.17
- NMAA allows vaccinated student athletes to compete without masks - Friday 6.17
- 60% fully vax declared Friday 6.18.21; reached 60% on dashboard Wednesday 6.23.21
- Texas data added to NMSIS Tuesday 6.29.21: 22,908 first doses, 12,104 second doses and 1,260 doses of J&J.
- Dashboard changes to reporting 18+ and 12 – 17 in separate categories – Thursday 7.8.21
- Second round of \$100 incentive announced Thursday, 7.29.21 and starts Monday 8.2.21
- “Additional Dose” of mRNA vaccine approved for immunocompromised individuals by CDC – Friday 8.13.21
- FDA grants full approval to Pfizer – Monday 8.23.21
- August Incentive ends 8.31.21; opt in period ends 9.10.21
- FDA VRBPAC authorizes Pfizer boosters for 65+ and high risk – Friday 9.17.21
- CDC recommends single Pfizer booster at 6 months for certain high-risk populations 9.23.21
- Dashboard metric changed from “age at time of vax” to “age now” and federal data added to race/ethnicity metric- 10.8.21
- VRBPAC recommends Moderna and J&J boosters 10.14 - 10.15.21
- CDC authorizes Moderna, J&J and Mix&Match boosters 10.22.21
- FDA authorizes pediatric Pfizer vaccine (for ages 5 – 11) on 10.29.21
- ACIP/CDC recommends pediatric Pfizer on 11.2.21
- Boosters open to all 18+ in NM Friday 11.12.21
- FDA/ACIP approve boosters for all 18+ 11.19.21

Timeline (cont.)

12.8.21	The F.D.A. authorizes AstraZeneca's <u>Evusheld</u> for emergency use
12.9.21	Pfizer boosters approved for 16 - 17 year olds
12.22.21	The F.D.A. authorizes Pfizer's Paxlovid for emergency use
12.23.21	The F.D.A. authorizes Merck's Molnupiravir for emergency use
12.23.21	CDC changes guidance for HCWs with COVID-19
12.27.21	CDC shortens isolation guidance for asymptomatic people to 5 days
1.3.22	The F.D.A. authorizes Pfizer vaccine boosters for everyone 12 and older and expanded 3rd dose for immune compromised individuals to include 5 - 11 year olds
1.3.22	The F.D.A changes Pfizer booster time frame to "at least 5 months from primary series completion".


COVID-19 Overview



Community Transmission
is based on cases/100K
and test positivity in the
last 7 days

[CDC COVID Data Tracker](#)

US COVID-19 7-Day Death Rate per 100,000, by State/Territory




[CDC COVID Data Tracker](#)

01/01/22

New Deaths from COVID per 100,000

NEW DEATHS PER 100,000




NATIONAL RANKING OF NEW DEATHS PER 100,000

National Rank	State	National Rank	State
1	MD	27	NY
2	OK	28	VA
3	AL	29	VT
4	FL	30	MO
5	PR	31	ND
6	DC	32	MA
7	AK	33	RI
8	LA	34	IL
9	HI	35	SD
10	MS	36	AR
11	KY	37	NV
12	CA	38	IA
13	TX	39	MI
14	NC	40	WY
15	WA	41	MN
16	NJ	42	NH
17	NE	43	CO
18	SC	44	TN
19	KS	45	ME
20	UT	46	WV
21	OR	47	OH
22	DE	48	WI
23	MT	49	PA
24	GA	50	IN
25	CT	51	AZ
26	ID	52	NM

Coronavirus Vaccine Tracker

By [Carl Zimmer](#), [Jonathan Corum](#), [Sui-Lee Wee](#) and Matthew Kristoffersen Updated Jan. 1, 2022



Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine

Dec 31, 2021

<https://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine>

PHASE 3

EMERGENCY USE IN EUROPE, INDONESIA, PHILIPPINES

NOVAVAX
Creating Tomorrow's Vaccines Today

VACCINE NAME: NVX-CoV2373 (also known as Covovax or Nuvaxovid)


EFFICACY: 90.4%

DOSE: 2 doses, 3 weeks apart

TYPE: Muscle injection

STORAGE: Stable in refrigerator


Weekly COVID-10 Vaccines Administered in NM since 12/24/20



National Picture: Vaccinations

PERCENT OF POPULATION FULLY VACCINATED

NATIONAL RANKING OF
POPULATION FULLY VACCINATED



National Rank	State	National Rank	State
1	VT	27	UT
2	PR	28	SD
3	RI	29	AZ
4	ME	30	KS
5	CT	31	TX
6	MA	32	MI
7	NY	33	NC
8	NJ	34	NV
9	MD	35	AK
10	VA	36	OH
11	WA	37	WV
12	DC	38	KY
13	NH	39	MT
14	OR	40	OK
15	NM	41	SC
16	CO	42	MO
17	CA	43	ND
18	MN	44	IN
19	DE	45	TN
20	IL	46	AR
21	PA	47	GA
22	HI	48	LA
23	FL	49	MS
24	WI	50	AL
25	NE	51	WY
26	IA	52	ID

STATE VACCINATION SUMMARY

DOSES DELIVERED3,788,835
180,694 per 100k**DOSES ADMINISTERED**3,403,081
162,297 per 100k**RECEIVED AT
LEAST ONE DOSE****FULLY
VACCINATED****RECEIVED
BOOSTER DOSE****ALL PEOPLE**1,681,126
80.2% of total population1,382,669
65.9% of total population517,982
37.5% of fully vaccinated total pop**PEOPLE 5-11**50,978
27.1% of 5-11 population28,380
15.1% of 5-11 population

N/A

PEOPLE 12-17122,947
73.9% of 12-17 population103,043
61.9% of 12-17 population

N/A

PEOPLE 18+1,507,030
93.0% of 18+ population1,251,197
77.2% of 18+ population515,635
41.2% of fully vaccinated 18+ pop**PEOPLE 65+**406,314
95.0% of 65+ population343,139
90.9% of 65+ population209,302
61.0% of fully vaccinated 65+ pop

Booster Updates



New booster recommendations


- ACIP meeting Wednesday, 1/5/22 on boosters for 12 - 15 year olds. FDA expanded EUA on Monday 1/3/22.
- Third dose approved for 5 - 11 year olds who are immune compromised.
- Pfizer boosters can be given at 5 months from primary series

State-wide Booster Progress

Number of New Mexicans 18+ with a booster dose	Percentage of New Mexicans 18+ with a booster dose	Percent of eligible New Mexicans 16+ with booster dose	Percent of eligible New Mexicans 65+ with booster dose
579,872	35.7% (whole pop denom)	57.0%	73.0%

As of 1/3/22


Booster Doses (includes Additional Doses) since 8.1.21



4.5 % increase
over previous
week

COVID19 Vaccines for 5-11 Year-olds

Vaccine administration for 5 - 11 year olds



Vaccine Updates

Transition to Pfizer Tris-sucrose Vaccine Formulation (Comirnaty)

“GRAY CAP”

Beginning December 23, CDC is planning to begin the transition to the Pfizer fully licensed vaccine formulation (Comirnaty) for ages 12+.

This formulation is expected to have:

- **gray** vial cap
- minimum order size of 300 doses
- does not require diluent
- 6-doses per vial
- same dose volume as the current purple cap (0.3mL)
- stable at 2°-8°C for up to 10 weeks. The product can also be stored at -90° – 60°C for up to 6 months

Please use up the purple cap Pfizer and update inventory in NMSIIS and Vfinder before ordering Tris-sucrose (Gray cap)

INVENTORY

- Please reconcile inventory weekly
- Reconcile inventory before ordering.
- If inventory shows too many doses, orders may be delayed or denied



EXPIRATION DATES

- Please be careful to put correct expiration dates when entering inventory. Doses come up as invalid when the expiration date is wrong
- Label and check refrigerated doses so they aren't used beyond Moderna's 30 day, Purple cap's 31 day or Orange cap's 10 week refrigerated expiry dates
- Please double check expiration date:
 - MODERNA:
<https://www.modernatx.com/covid19vaccine-eua/providers/vial-lookup>
 - PFIZER - no look up tool
 - J&J: <https://vaxcheck.jnj/>



For assistance:

1. Contact our NMSIIS Help Desk at (833) 882-6454
2. Email us at COVID.vaccines@state.nm.us
3. Resource guide in the NMSIIS Reports section



CDC Guidance on Isolation and Quarantine

- NM DOH guidance will be issued on Wednesday 1/5/22
- Call Center and Contact Tracing will implement new guidance on Thursday 1/6/22

CDC Shortens Recommended Quarantine and Isolation for the General Population

If You Test Positive for COVID-19 (Isolate)

Everyone, regardless of vaccination status.

- Stay home for 5 days.
- If you have no symptoms or your symptoms are resolving after 5 days, you can leave your house.
- Continue to wear a mask around others for 5 additional days.

If you have a fever, continue to stay home until your fever resolves.

<https://www.cdc.gov/media/releases/2021/s1227-isolation-quarantine-guidance.html>

If You Were Exposed to Someone with COVID-19 (Quarantine)

If you:

Have been boosted

OR

Completed the primary series of Pfizer or Moderna vaccine within the last 6 months

OR

Completed the primary series of J&J vaccine within the last 2 months

- Wear a mask around others for 10 days.
- Test on day 5, if possible.

If you develop symptoms get a test and stay home.

If you:

Completed the primary series of Pfizer or Moderna vaccine over 6 months ago and are not boosted

OR

Completed the primary series of J&J over 2 months ago and are not boosted

OR

Are unvaccinated

- Stay home for 5 days. After that continue to wear a mask around others for 5 additional days.
- If you can't quarantine you must wear a mask for 10 days.
- Test on day 5 if possible.

If you develop symptoms get a test and stay home

Rapid Antigen Testing (home tests)

Positive Test Result: Regardless of Vaccination Status

- ❑ Consider yourself positive for COVID-19. **You do not need to get an additional PCR test.**
- ❑ Stay home for 5 days since the start of symptoms (or a positive test)
- ❑ If you have no more symptoms, after 5 days, you can leave your house **BUT wear a mask for 5 more days**
- ❑ Contact people who you have had recent close contact with and notify them that you have COVID-19.



Negative Test: With Symptoms

- ❑ Confirm your results with a second test:
 - ➔ PCR tests are recommended.
 - ➔ Or take another at-home test 1-2 days later.
- ❑ If your additional test is positive, follow the guidelines for a positive test.

Know the symptoms of COVID-19, which can include the following:



Negative Test: No Symptoms

- ❑ A negative self-test means that the test did not detect the virus.
- ❑ If you have NOT been exposed to COVID-19 recently, no other action is needed at this time.



Negative Test: No Symptoms WITH a COVID Exposure

If you have a negative at-home test result, **but have been recently exposed to COVID-19:**



Fully vaccinated people with a booster shot: “Up to Date”

1. Do not need to stay at home.
2. Need to wear a mask for ten days
3. If symptoms develop, get tested on day 5 and stay at home while waiting for results.

People not fully vaccinated against COVID-19 or who are vaccinated but not boosted need to:



1. Test on day 5
2. Stay at home for 5 days
3. Wear a mask for an additional 5 days.

How to Prevent the Spread of COVID-19

When you stay at home because of COVID



Stay in a room away from other people in your home and use a different bathroom if possible. Wear a face mask at all times if you don't have another room.



Avoid sharing items with others in your household, and eat on your own.



Clean surfaces that are used often (counters, tabletops, doorknobs, bathrooms).



Cover your cough and sneezes.

Antivirals Update

← → ↻ 🏠 🔒 https://cv.nmhealth.org

Select Language ▼

Public Health Orders Medical & Scientific Reports COVID Safe Instructions County Data nmhealth.org NewMexico.gov

Newsroom & Updates COVID-19 Testing COVID-19 Vaccine COVID-19 Treatment Provider Info About COVID-19

NMDOH Coronavirus Disease 2019 in New Mexico

Do you want to pre-register for your COVID-19 Vaccine? Visit cvvaccine.nmhealth.org to register today.

NM NOTIFY Want to help prevent the spread of COVID-19? Visit nmnotify.com to Add Your Phone to the Fight Against COVID-19!

Self Test Information – Everything you need to know about self tests.

2019 Novel Coronavirus Disease (COVID-19)
COVID-19 is a highly infectious and fast-spreading virus. Symptoms and their effects can range from mild to severe and in certain cases result in extreme health complications and death.

Latest COVID News:
New Mexico COVID-19 update: **7,313 new cases, totaling 357,480**
Jan 3, 2022

[POLICIES FOR THE PREVENTION & CONTROL OF COVID-19 IN NEW MEXICO](#)

[Information for Providers | NMDOH - Coronavirus Updates \(nmhealth.org\)](https://nmhealth.org)

Antiviral distribution - Phase Criteria

Who is in Phase 1?

Paxlovid Patient Criteria:

- Treatment can be started within 5 days or less from symptom onset AND
- Positive COVID-19 test AND
- Must reside in an eligible county AND
- **OMASS score of 6 or greater OR**
- **12-17 years of age and OMASS score of 3 or greater**

Molnupiravir Patient Criteria:

- Treatment can be started within 5 days or less from symptom onset AND
- Positive COVID-19 test AND
- Must reside in an eligible county AND
- **OMASS score 3 or greater**

[COVID-19 Oral Treatments | NMDOH - Coronavirus Updates \(nmhealth.org\)](https://nmhealth.org/COVID-19-Oral-Treatments)

OMASS score

Oral Antiviral & Monoclonal Antibody Screening Score (OMAS)
adapted from Mayo Clinic's published Monoclonal Antibody Screening Score (MASS)

RISK FACTOR	POINTS
Age 65 years and older	2
BMI 35 kg/m2 and higher	2
Diabetes mellitus	2
Chronic kidney disease	3
Cardiovascular disease in a patient 55 years and older	2
Chronic respiratory disease in a patient 55 years and older	3
Hypertension in a patient 55 years and older	1
Immunosuppressed and unlikely to have responded to vaccines (eg: CD20 inhibitors, BTK inhibitors, campath, recent CAR-T, organ transplant)	3
Pregnancy*	4
BIPOC (Black, Indigenous, People of Color) status	1

** Molnupiravir is not recommended for use in pregnancy.*

ORAL THERAPEUTICS

PAXLOVID (Pfizer product)

- EUA 12.22.21
- expected allocation: 174 course/week (delivered as 348 doses/2 weeks)
- 88% effective at decreasing hospitalization if given within 5 days
- efficacy not affected by Omicron
- distribution through Walgreens

MOLNUPIRAVIR (Merck product)

- EUA 12.23.21
- expected allocation: 770 courses/week (delivered as 1540/2 weeks)
- 30% effective at decreasing hospitalization if given within 5 days
- efficacy not affected by Omicron
- distribution through Walgreens

COVID PrEP Overview

COVID Pre-exposure prophylaxis (PrEP) Overview

On December 08, 2021, the Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older and weighing at least 40 kilograms.) This product is only authorized for use among individuals who are not currently infected with SARS-CoV-2 virus and have not recently been exposed to an individual infected with SARS-CoV-2. The EUA requires that individuals either have:

- Moderate to severely compromised immune system due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination OR
- A history of severe adverse reactions to a COVID-19 vaccine and/or component(s) where administration of the vaccine is not recommended.

Evusheld is not authorized for individuals for the treatment of COVID-19 or for post-exposure prevention of COVID-19. Pre-exposure prophylaxis with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended, including those with moderate to severe immunocompromising conditions. For individuals who have received a COVID-19 vaccine, Evusheld should be administered at least two weeks after vaccination. For additional information see: [FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR EVUSHELD™ \(tixagevimab co-packaged with cilgavimab\) \(fda.gov\)](#)

Additional Information

What are you looking for?

- [Frequently Asked Questions](#)
- [COVID PrEP Required Reporting](#)
- [COVID PrEP Distribution](#)
- [Clinical Resources](#)
- [Directory of COVID PrEP Providers](#)
- [COVID PrEP Billing](#)
- [Weekly HHS Office Hours](#)
- [Additional Resources](#)

LINK TO PROVIDER INFORMATION:

<https://cv.nmhealth.org/providers/covid-prep-information-for-providers/>

EVUSHELD (formerly AZD7442)

- EUA 12/8/21
- COVID pre-exposure prophylaxis
- For people who are moderately to severely immunocompromised and are not expected to mount an immune response to COVID-19 vaccines
- For those in whom COVID-19 vaccine is contraindicated.
- Approved for ages 12+ weighing at least 40kg
- Combo of 2 long acting MABS
- IM injection with repeat dosing every 6 months
- Not a substitute for vaccine
- Expecting 320 doses every 2 weeks
- Distributed to relevant specialists who signed up to be providers
- Some decrease in efficacy against Omicron



From HHS: Side-by-Side Overview of Outpatient Therapies . . .

Product	Casirivimab/Imdevimab (REGEN-COV®) Monoclonal Antibodies	Bamlanivimab/Etesevimab Monoclonal Antibodies	Sotrovimab Monoclonal Antibodies	PAXLOVID® Oral Antivirals	Molnupiravir Oral Antivirals
Manufacturer	Regeneron Pharmaceuticals, Inc.	Eli Lilly and Company	GlaxoSmithKline plc / Vir Biotechnology, Inc.	Pfizer Inc.	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Date of First EUA ¹ Issuance	11/21/20	2/9/21	5/26/21	12/22/21	12/23/21
Mechanism of Action	mAbs against spike protein; blocks viral attachment to host cells	mAbs against spike protein; blocks viral attachment to host cells	mAbs against spike protein; blocks viral entry	Viral protease inhibitor that halts viral replication.	Nucleoside analog that inhibits viral replication by viral mutagenesis
Treatment Efficacy per Clinical Trials ²	70% reduction in hospitalizations/deaths	87% reduction in hospitalizations/deaths	79% reduction in hospitalizations/deaths	88% reduction in hospitalizations/deaths	30% reduction in hospitalizations/deaths
Activity Against SARS-CoV- 2 Variants	<i>Delta variant:</i> Active <i>Omicron variant:</i> unlikely to be active <i>Other variants:</i> See Section 15 of REGEN-	<i>Delta variant:</i> Active <i>Omicron variant:</i> unlikely to be active <i>Other variants:</i> See Section 15 of	<i>Delta variant:</i> Active <i>Omicron variant:</i> likely active <i>Other variants:</i> See Section 15 of	<i>Delta variant:</i> Active <i>Omicron variant:</i> Data pending <i>Other variants:</i> See Section 12.4 of PAXLOVID	<i>Delta variant:</i> Active <i>Omicron variant:</i> Data pending <i>Other variants:</i> See Section 12.4 of

Other Resources for tracking COVID-19 Treatment

We are following 33 coronavirus treatments for effectiveness and safety:



<https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html>



San Rafael, CA

Questions:
covid.vaccines@state.nm.us

THANK YOU!